Annovis Bio (ANVS) Surges 15.17% Pre-Market on Phase 3 Alzheimer's Trial Progress

Annovis Bio’s shares surged 15.17% in pre-market trading on November 13, 2025, signaling renewed investor optimism ahead of key developments.

The rally coincided with updates on the biotech firm’s Phase 3 Alzheimer’s trial, where all 84 U.S. sites are now active, and the first patient cohort completed six months of treatment. Analysts highlighted the progress as a critical milestone for buntanetap, the company’s drug candidate, which has demonstrated anti-inflammatory effects in early data. CEO Maria-Luisa Maccecchini’s recent $200,000 insider purchase further bolstered confidence, while Q3 financials showed $15.3 million in cash reserves, sufficient to fund operations through Q3 2026.

Despite a Q3 earnings miss, institutional activity remains mixed: 19 investors added shares, while 18 reduced holdings. Buy ratings from Canaccord Genuity and HC Wainwright, alongside a $13.5 median price target, reflect cautious optimism about long-term potential. The stock’s 36% six-month rebound and 72% annual decline underscore its volatility.

Backtesting suggests a momentum-driven strategy could capitalize on the recent breakout. A 50-day moving average crossover above the 200-day line, coupled with elevated volume during the pre-market surge, supports a bullish bias. However, liquidity constraints and regulatory risks in Alzheimer’s trials remain key hurdles.